SPRY
ARS Pharmaceuticals, Inc.
$6.44
-0.56
(-8.00%)
Mkt Cap
639.51M
Volume
2,932,953
52W Range
6.42-18.63
Sector
Healthcare
Beta
0.88
EPS (TTM)
-2.01
P/E Ratio
-6.70
Revenue (TTM)
98.99M
Rev Growth (5Y)
+36.4%
EPS Growth (5Y)
N/A
Company Description
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.28M | 89.15M | 30,000 | 1.32M | 5.51M | 17.84M | 0 | 0 |
| Net Income | (171.30M) | 8.00M | (54.37M) | (34.68M) | (20.24M) | (1.06M) | (23.97M) | (17.58M) |
| EPS | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -0.03 | -0.72 | -0.53 |
| Free Cash Flow | (171.21M) | 12.98M | (59.44M) | (40.28M) | (17.62M) | 8.15M | (18.99M) | (17.32M) |
| FCF / Share | -1.74 | 0.13 | -0.62 | -1.01 | -0.61 | 0.23 | -0.57 | -0.52 |
| Operating CF | (170.87M) | 13.55M | (59.27M) | (40.08M) | (17.56M) | 9.07M | (18.90M) | (16.88M) |
| Total Assets | 327.65M | 351.15M | 233.19M | 281.44M | 61.45M | 26.41M | 15.65M | 27.55M |
| Total Debt | 96.37M | 42,000 | 274,000 | 481,000 | 9.03M | 10.02M | 15.62M | 7.73M |
| Cash & Equiv | 41.32M | 50.82M | 70.97M | 210.52M | 60.06M | 24.52M | 9.98M | 20.16M |
| Book Value | 114.26M | 256.80M | 230.76M | 272.89M | (31.27M) | (14.05M) | (5.60M) | 18.20M |
| Return on Equity | -1.50 | 0.03 | -0.24 | -0.13 | N/A | N/A | N/A | -0.97 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.68M | 28.09M | 32.50M | 15.72M | 7.97M | 86.58M | 2.07M | 500,000 | 0 | 0 | 0 | 10,000 |
| Net Income | (60.62M) | (41.32M) | (51.15M) | (44.88M) | (33.94M) | 49.93M | (19.13M) | (12.52M) | (10.29M) | (7.17M) | (14.87M) | (17.37M) |
| EPS | -0.61 | -0.42 | -0.52 | -0.46 | -0.35 | 0.51 | -0.20 | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 |
| Free Cash Flow | (44.95M) | (43.48M) | (47.24M) | (39.64M) | (40.83M) | 41.70M | (14.61M) | (7.32M) | (6.79M) | (17.31M) | (12.81M) | (16.70M) |
| FCF / Share | -0.45 | -0.44 | -0.48 | -0.40 | -0.42 | 0.43 | -0.15 | -0.08 | -0.07 | -0.18 | -0.13 | -0.18 |
| Operating CF | (44.95M) | (43.48M) | (47.05M) | (39.59M) | (40.74M) | 42.00M | (14.47M) | (7.28M) | (6.71M) | (17.41M) | (12.76M) | (16.67M) |
| Total Assets | 287.57M | 327.65M | 372.80M | 313.47M | 327.32M | 351.15M | 217.60M | 221.97M | 227.58M | 233.19M | 248.56M | 258.75M |
| Total Debt | 96.52M | 96.37M | 1.53M | 1.66M | 73,000 | 42,000 | 102,000 | 160,000 | 217,000 | 274,000 | 327,000 | 379,000 |
| Cash & Equiv | 24.32M | 41.32M | 59.56M | 51.54M | 39.86M | 50.82M | 39.66M | 36.63M | 56.01M | 70.97M | 60.53M | 119.02M |
| Book Value | 61.31M | 114.26M | 147.66M | 192.32M | 228.97M | 256.80M | 200.98M | 215.24M | 223.87M | 230.76M | 237.28M | 248.55M |
| Return on Equity | -0.99 | -0.36 | -0.35 | -0.23 | -0.15 | 0.19 | -0.10 | -0.06 | -0.05 | -0.03 | -0.06 | -0.07 |
SPRY News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
Can ARS Pharma's New CEO Unlock Neffy's Potential?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
ARS Pharmaceuticals Announces CEO Succession
ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY